UroGen (URGN): Rasio kapitalisasi pasar marang pendapatan
The price-to-sales valuation clearly demonstrates the impact of stringent FDA requirements and patent protection on UroGen Pharma Ltd. (URGN) dynamics, with 5.10 serving as the current value of the metric. High physician confidence in urothelial therapy confirms the company's status as an innovator, while the unique hydrogel enables seamless global business scaling with minimal production costs.
Rincian metrik lan analitis perusahaan UroGen Pharma (URGN)
- nilai saham lan prakiraan konsensus rega:
- data kapitalisasi bursa:
- indikator kapitalisasi buku:
- indikator beban kredit lan likuiditas emiten:
Utang marang Modal UroGen Pharma Ltd.|URGN - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang modal UroGen Pharma|URGN - Gunggung utang perusahaan|Rasio utang marang aset resik UroGen Pharma|URGN - Utang jangka dawa perusahaan|Kewajiban jangka cendhak UroGen Pharma|Rasio jangkoan perantara urogen.com
- data bathi lan kelipatan valuasi:
URGN - Bathi resik|Proyeksi bathi mangsa ngarep UroGen Pharma Ltd.|URGN - Rasio rega marang bathi|Pangali mangsa ngarep rega marang bathi UroGen Pharma Corp|URGN - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan UroGen Pharma Corp|URGN - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) UroGen Pharma|URGN - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan urogen.com|URGN - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep UroGen Pharma Ltd.
- rincian pendapatan lan dodolan emiten:
Ringkesan analitik perusahaan:UroGen Pharma Ltd, URGN
The P/S ratio reflects the market value of a business relative to its revenue, allowing for an assessment of an asset's fair value through the lens of generated sales. Analyzing the median P/S helps compare the capitalization of UroGen Pharma Ltd. (URGN) with the efficiency of its modernized oncology drug production facilities, determining whether the stock price is justified by current capacity utilization and revenue growth rates.
Pesaing UroGen Pharma Ltd.
ONC - Rega marang dodolan|Multiplikator P/S HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Rega marang dodolan|ascentage.com - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan CGON (cgoncology.com)|BCAX: Multiplikator P/S|PSNL - Koefisien rega marang pendapatan|ERAS (Erasca Oncology) - Multiplikator P/S|Multiplikator P/S Delcath Systems, Inc.|Rasio rega marang pendapatan ymabs.com (YMAB)|Rasio rega marang pendapatan AURA (Aura Biosciences, Inc.)|Candel Therapeutics - Kapitalisasi marang pendapatan|Accuray Inc. (ARAY) - Rega marang dodolan|SELLAS Life Sciences Group, Inc. - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan ACTU (Actuate Therapeutics, Inc.)|Citius Oncology (CTOR) - Rasio rega marang pendapatan|HURA - Koefisien rega marang pendapatan|TARA (Protara Therapeutics, Inc.) - Multiplikator P/S|Multiplikator P/S Fate Therapeutics Inc|Multiplikator P/S WHWK|Multiplikator P/S TScan Therapeutics Inc (TCRX)|Rasio rega marang pendapatan championsoncology.com CSBR|XBIT - Kapitalisasi marang pendapatan|CVM - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan OSTX (OS Therapies)|RADX: Multiplikator P/S|Artiva Biotherapeutics Inc. - Rasio kapitalisasi pasar marang pendapatan|ANL (Adlai Nortye) - Multiplikator P/S|Multiplikator P/S verupharma.com|Kapitalisasi marang pendapatan TPST (tempesttx.com)|Kapitalisasi marang pendapatan Xilio Therapeutics Inc XLO|Multiplikator P/S RENB (Enochian BioSciences)|Mural Bio - Rasio rega marang pendapatan|KAPA - Rasio rega marang pendapatan|OnKure Therapeutics (OKUR) - Kapitalisasi marang pendapatan|GDTC: Multiplikator P/S|Rega marang dodolan Curis Corp (CRIS)|APLM (apollomicsinc.com) - Multiplikator P/S|Kapitalisasi marang pendapatan Tharimmune Corp (THAR)|Multiplikator P/S ADVB|GNPX - Rega marang dodolan|Rasio rega marang pendapatan calidibio.com CLDI|SBFM - Kapitalisasi marang pendapatan|XBIO - Rasio rega marang pendapatan|SLRX: Rasio rega marang pendapatan|Purple Biotech (PPBT) - Rasio rega marang pendapatan|AON - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan BGNE|Multiplikator P/S Checkpoint Therapeutics Inc.|Multiplikator P/S ELEV|Kapitalisasi marang pendapatan iCAD ICAD|Multiplikator P/S IKNA (Ikena Oncology, Inc.)|Rasio kapitalisasi pasar marang pendapatan NTBL|Viracta Therapeutics, Inc. - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Kapitalisasi marang pendapatan|Kapitalisasi marang pendapatan Ascentage Pharma Group Ltd
